Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

News Eli Lilly and Company

Equities

LLY

US5324571083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-15 pm EDT 		5-day change 1st Jan Change
750.8 USD -0.12% Intraday chart for Eli Lilly and Company -3.41% +28.79%
Apr. 12 European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
Apr. 12 BMO Raises Price Target on Eli Lilly to $900 From $865 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm
RE
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs
MT
BMO Raises Price Target on Eli Lilly to $900 From $865
MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts
RE
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal
CI
Goldman Sachs Raises Price Target on Eli Lilly to $723 From $650, Maintains Neutral Rating
MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says
RE
Gerresheimer expects sales boost from burgeoning obesity drugs sector
RE
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review
DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation
MT
Bayer - AskBio Names Mansuo Shannon Chief Scientific Officer
AQ
Sector Update: Health Care Stocks Decline Late Afternoon
MT
Sector Update: Health Care Stocks Softer Monday Afternoon
MT
Sector Update: Health Care
MT
Eli Lilly Kicks Off Construction of Plant in Germany to Boost Weight-Loss Drug Production
MT
Eli Lilly Starts Construction of EUR2.3 Billion Production Plant in Germany
MT
Lilly - Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance on risk of heart failure hospitalization and death in adults following a heart attack
AQ
Eli Lilly and : Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company